Nanoacarreadores
Novedoso enfoque en la lucha contra la enfermedad de chagas
Palabras clave:
Enfermedad de Chagas, nanopartículas, partículas tipo viral, Trypanosoma cruzi
Resumen
Chagas disease is a little known disease, transmitted by a parasite named Trypanosoma cruzi. In 2005, the World Health Organization declared it a neglected disease, which contributed to spreading knowledge about the characteristics of the disease, as well as supporting scientific research into new and better treatments, early diagnosis, detection and care of people with the disease. In the field of scientific research, particles smaller than viruses are being studied, in order to efficiently carry already tested drugs; but also with the application of this nanotechnology, to the use of nanocarriers that manage to reach the parasite and modify its way of reproduction or infection, thus fighting the disease.
Descargas
La descarga de datos todavía no está disponible.
Citas
Britto Hurtado, R., Cortez Valadez, M., & Flores Acosta, M. (2022). Aplicaciones tecnológicas de las nanopartículas en la medicina e industria. Epistemus, 16(33).
Cárdenas-Guerra, R. E., Moreno-Gutierrez, D. S., Vargas-Dorantes, O. J., Espinoza, B., & Hernandez-Garcia, A. (2020). Delivery of antisense DNA into pathogenic parasite Trypanosoma cruzi using virus-like protein-based nanoparticles. Nucleic acid therapeutics, 30(6), 392–401.
Jekhmane, S., de Haas, R., Paulino da Silva Filho, O., van Asbeck, A. H., Favretto, M. E., Hernandez Garcia, A., Brock, R., & de Vries, R. (2017). Virus-like particles of mRNA with artificial minimal coat proteins: particle formation, stability, and transfection efficiency. Nucleic acid therapeutics, 27(3), 159–167.
Juárez-Chávez, L., Pina-Canseco, S., Soto-Castro, D., Santillan, R., Magaña-Vergara, N. E., Salazar-Schettino, P. M., Cabrera-Bravo, M., & Pérez-Campos, E. (2019). In vitro activity of steroidal dendrimers on Trypanosoma cruzi epimastigote form with PAMAM dendrons modified by "click" chemistry. Bioorganic chemistry, 86, 452–458.
Morilla, M. J., Romero, E. L. (2015). Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine, 10(3), 465–481.
Muraca GS, Talevi A, Pesce GO. (2020). Enfermedad de Chagas: novedades en naomedicinas como estrategia terapéutica. Ciencia Reguladora, Abr (6): 32-37.
Pautler, M., & Brenner, S. (2010). Nanomedicine: promises and challenges for the future of public health. International journal of nanomedicine, 5, 803–809.
Scalise ML, Arrúa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. (2016). Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model: In-vitro and in-vivo studies. Am J Trop Med Hyg, Aug 1;95(2):388–393.
Silva, J. J., Guedes, P. M., Zottis, A., Balliano, T. L., Nascimento Silva, F. O., França Lopes, L. G., Ellena, J., Oliva, G., Andricopulo, A. D., Franco, D. W., & Silva, J. S. (2010). Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. British journal of pharmacology, 160(2), 260–269.
Stass, H., Ince, I., Grossmann, U., Weimann, B., & Willmann, S. (2022). Nifurtimox for treatment of chagas disease in pediatric patients: the challenges of applying pharmacokinetic-pharmacodynamic principles to dose finding. The AAPS journal, 24(5), 92.
Cárdenas-Guerra, R. E., Moreno-Gutierrez, D. S., Vargas-Dorantes, O. J., Espinoza, B., & Hernandez-Garcia, A. (2020). Delivery of antisense DNA into pathogenic parasite Trypanosoma cruzi using virus-like protein-based nanoparticles. Nucleic acid therapeutics, 30(6), 392–401.
Jekhmane, S., de Haas, R., Paulino da Silva Filho, O., van Asbeck, A. H., Favretto, M. E., Hernandez Garcia, A., Brock, R., & de Vries, R. (2017). Virus-like particles of mRNA with artificial minimal coat proteins: particle formation, stability, and transfection efficiency. Nucleic acid therapeutics, 27(3), 159–167.
Juárez-Chávez, L., Pina-Canseco, S., Soto-Castro, D., Santillan, R., Magaña-Vergara, N. E., Salazar-Schettino, P. M., Cabrera-Bravo, M., & Pérez-Campos, E. (2019). In vitro activity of steroidal dendrimers on Trypanosoma cruzi epimastigote form with PAMAM dendrons modified by "click" chemistry. Bioorganic chemistry, 86, 452–458.
Morilla, M. J., Romero, E. L. (2015). Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine, 10(3), 465–481.
Muraca GS, Talevi A, Pesce GO. (2020). Enfermedad de Chagas: novedades en naomedicinas como estrategia terapéutica. Ciencia Reguladora, Abr (6): 32-37.
Pautler, M., & Brenner, S. (2010). Nanomedicine: promises and challenges for the future of public health. International journal of nanomedicine, 5, 803–809.
Scalise ML, Arrúa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. (2016). Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model: In-vitro and in-vivo studies. Am J Trop Med Hyg, Aug 1;95(2):388–393.
Silva, J. J., Guedes, P. M., Zottis, A., Balliano, T. L., Nascimento Silva, F. O., França Lopes, L. G., Ellena, J., Oliva, G., Andricopulo, A. D., Franco, D. W., & Silva, J. S. (2010). Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. British journal of pharmacology, 160(2), 260–269.
Stass, H., Ince, I., Grossmann, U., Weimann, B., & Willmann, S. (2022). Nifurtimox for treatment of chagas disease in pediatric patients: the challenges of applying pharmacokinetic-pharmacodynamic principles to dose finding. The AAPS journal, 24(5), 92.
Publicado
2025-04-09
Cómo citar
Prestegui Martel, B., & Espinoza Gutiérrez, B. (2025). Nanoacarreadores: Novedoso enfoque en la lucha contra la enfermedad de chagas. Contactos, Revista De Educación En Ciencias E Ingeniería, (141), 37 - 44. Recuperado a partir de https://contactos.izt.uam.mx/index.php/contactos/article/view/518
Sección
Artículos
